Accueil>>Signaling Pathways>> Others>>ML-290

ML-290 (Synonyms: RXFP1 Agonist 8​​)

Catalog No.GC18594

Le ML-290 est un puissant agoniste et activateur des récepteurs peptidiques de la famille de la relaxine/insuline (RXFP1) et activateur des gènes anti-fibrotiques, avec une CE50 de 94 nM.

Products are for research use only. Not for human use. We do not sell to patients.

ML-290 Chemical Structure

Cas No.: 1482500-76-4

Taille Prix Stock Qté
1mg
53,00 $US
En stock
5mg
168,00 $US
En stock
10mg
284,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ML-290 is an allosteric agonist of relaxin family peptide receptor 1 (RXFP1; EC50 = 94 nM for human RXFP1).[1],[2] It displays >15-fold selectivity for RXFP1 over RXFP2.[2] ML-290 activates human, rhesus macaque, pig, and rabbit RXFP1 but is weak or inactive at mouse or guinea pig RXFP1.[2],[3] Through RXFP1, ML-290 increases intracellular cAMP and induces VEGF expression (2.8-fold at 250 nM).[2] ML-290 is metabolically stable and displays excellent in vivo pharmacokinetics.[2]

Reference:
[1]. Paredes, R.M., Etzler, J.C., Watts, L.T., et al. Chemical calcium indicators. Methods 46(3), 143-151 (2008).
[2]. Minta, A., Kao, J.P., and Tsien, R.Y. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. The Journal of Biological Chemisty 264(14), 8171-8178 (1989).

Avis

Review for ML-290

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ML-290

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.